Singapore, Mar 31, 2010: Avita Medical has secured regulatory approval for its ReCell Autologous Spray-On Skin from the Taiwan Ministry of Health.

The Ministry of Health is the Taiwanese equivalent of British MHRA and USFDA and is responsible for regulation and supervision of medical products and is the competent authority for device regulation.

In a release, Avita said Taiwan was a significant market for the company. Besides treating burns and other acute wounds, ReCell will also target the growing demand for aesthetic surgery, scar revision and dermal treatments for the aging population. The product focus is on Taiwan’s burgeoning middle class, an affluent and rapidly growing segment of the country’s 23 million people.

The target market for ReCell includes plastic and reconstructive surgeons, dermatologists, burns specialists and cosmetic specialists at private, public and military hospitals and clinics.

ReCell will be distributed through Shaw Han, a major provider of medical equipment and disposable products for surgical and aesthetic applications in Taiwan. Shaw Han was instrumental in successfully completing the highly complex Taiwanese approval and registration process.

Dr William Dolphin, CEO of Avita Medical, said, “The ReCell technology has strong sales potential in Taiwan where the cosmetics and plastics markets are growing exponentially. Taiwan is a very attractive market for our product.”